Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Cerevel Therapeutics (Cerevel), a subsidiary of AbbVie Inc, is a clinical-stage biopharmaceutical ... and darigabat targets epilepsy and panic disorder; tavapadon for both early and late-stage ...

Also of note, AbbVie announced strong Phase III results of tavapadon in early Parkinson’s disease. Unfettered access to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary ... Not every drug that is in AbbVie's pipeline is going to be a success. But this is still a ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...

KOLs have expressed positive sentiments of tavapadon. Credit: Owlie Productions via Shutterstock. On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial ...

Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy ...

AbbVie offers a compelling investment opportunity ... in schizophrenia and novel neuroscience therapies such as tavapadon for Parkinson’s diseases. ABBV’s neuroscience capabilities are ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...